PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Core Insights - PainReform Ltd. announced early safety results from its Phase 3 bunionectomy study of PRF-110, showing promising outcomes for post-surgical pain management [1][3] - The study involved 443 patients across eight clinical sites in the U.S., demonstrating a low incidence of adverse events, averaging one per subject [2] Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, with PRF-110 as its lead product targeting postoperative pain relief [4] - PRF-110 is based on the local anesthetic ropivacaine and is designed to provide localized and extended postoperative analgesia through an oil-based, viscous solution [4] Market Potential - The company aims to address the $12 billion postoperative pain market with PRF-110, which is positioned as a non-opioid alternative in pain management [3] - The safety profile of PRF-110 is supported by extensive clinical and preclinical testing, enhancing its potential as a market leader [3]